Create Free Account

By creating account you will get access to hot stocks & personalised emails

Oncosil Medical Ltd

Healthcare AU OSL

0.006AUD
-0.001(14.29%)

Last update at 2024-12-19T05:11:00Z

Day Range

0.0060.007
LowHigh

52 Week Range

0.0040.01
LowHigh

Fundamentals

  • Previous Close 0.007
  • Market Cap31.48M
  • Volume4244158
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.97617M
  • Revenue TTM1.57M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM -0.12135M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -11.34293M -10.72670M -10.43352M -4.26189M -8.56673M
Minority interest - - - - -
Net income -11.34293M -10.72670M -10.43352M -4.26189M -4.68307M
Selling general administrative 6.56M 6.80M 5.97M 1.70M 5.62M
Selling and marketing expenses 0.13M 0.37M 0.68M 0.68M -
Gross profit -1.22110M -0.74069M -0.74795M -0.74795M 3.63M
Reconciled depreciation 0.18M 0.13M 0.18M 0.15M 0.04M
Ebit -11.34292M -11.53623M -10.43244M -4.26103M -12.45039M
Ebitda -11.16703M -11.40932M -10.24766M -4.11175M -12.41178M
Depreciation and amortization 0.18M 0.13M 0.18M 0.15M 0.04M
Non operating income net other - - - - -
Operating income -11.33549M -10.57772M -10.54189M -4.26103M -12.45039M
Other operating expenses 9.68M 9.84M 9.88M 7.36M 12.45M
Interest expense 0.00001M 0.00949M 0.00108M 0.00086M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.07M 0.01M 0.08M 0.01000M 0.01M
Net interest income 0.05M -0.00949M 0.08M -0.00086M 0.20M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.16M -0.11742M 1.13M 2.85M -3.88366M
Total revenue 0.37M 0.23M 0.21M 0.21M 3.83M
Total operating expenses 11.51M 10.80M 11.06M 7.36M 12.45M
Cost of revenue 1.59M 0.97M 0.96M 0.96M -
Total other income expense net 1.16M 0.69M 1.13M 2.85M 3.88M
Discontinued operations - - - - -
Net income from continuing ops -11.34293M -10.72670M -10.43352M -4.26189M -8.56673M
Net income applicable to common shares -11.34293M -10.72670M -10.43352M -4.26189M -8.56673M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 6.36M 11.47M 13.07M 14.15M 24.06M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.39M 0.12M 0.47M 0.11M 0.07M
Total liab 1.77M 1.59M 1.91M 2.45M 2.16M
Total stockholder equity 4.59M 9.88M 11.16M 11.70M 21.90M
Deferred long term liab - - - - -
Other current liab 0.79M 0.61M 0.84M 0.91M 0.80M
Common stock 90.09M 86.51M 79.91M 70.40M 70.14M
Capital stock - 86.51M 79.91M 70.40M 70.14M
Retained earnings -93.19216M -84.36754M -73.02461M -62.29791M -51.86438M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 4.50M 9.39M 11.28M 12.24M 21.00M
Cash and equivalents - - - - -
Total current liabilities 1.73M 1.57M 1.77M 2.13M 2.16M
Current deferred revenue 0.00000M -0.14625M -0.16537M -0.16324M -0.10994M
Net debt -4.43073M -9.22302M -10.97563M -11.75547M -20.88804M
Short term debt 0.03M 0.15M 0.17M 0.16M 0.11M
Short long term debt - - - - 0.03M
Short long term debt total 0.07M 0.17M 0.30M 0.48M 0.11M
Other stockholder equity - -2.13979M -6.88512M -8.09941M -18.27293M
Property plant equipment - 0.24M 0.32M 0.53M 0.14M
Total current assets 6.25M 11.23M 12.74M 13.62M 23.92M
Long term investments - - - - -
Net tangible assets - 9.88M 11.16M 11.70M 21.90M
Short term investments - 0.12M 0.09M 0.09M 0.07M
Net receivables 1.35M 1.29M 0.91M 1.18M 2.81M
Long term debt - - - - -
Inventory - - - - -0.02067M
Accounts payable 0.91M 0.96M 0.93M 1.23M 1.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.69M 7.74M 4.28M 3.60M 3.63M
Additional paid in capital - - - - -
Common stock total equity - - - - 70.14M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.23926M -0.32493M -0.53078M -0.13837M
Deferred long term asset charges - - - - -
Non current assets total 0.11M 0.24M 0.32M 0.53M 0.14M
Capital lease obligations - 0.17M 0.30M 0.48M 0.08M
Long term debt total - 0.02M 0.14M 0.32M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.05782M -0.00583M -0.05400M -0.02072M -0.01483M
Change to liabilities -0.07853M -0.07431M -0.04932M 1.01M -0.81644M
Total cashflows from investing activities -0.05782M -0.00583M -0.05400M -0.02072M -0.01483M
Net borrowings -0.18721M -0.16023M -0.14875M -0.09453M -0.09453M
Total cash from financing activities 9.49M 9.16M 0.11M 17.79M 17.79M
Change to operating activities -0.07517M -0.45532M 1.54M 1.04M 0.76M
Net income -11.34293M -10.72670M -10.43352M -4.26189M -8.56673M
Change in cash -1.88601M -0.96000M -8.75815M 13.31M -7.51598M
Begin period cash flow 11.28M 12.24M 21.00M 7.69M 15.21M
End period cash flow 9.39M 11.28M 12.24M 21.00M 7.69M
Total cash from operating activities -11.31563M -10.11018M -8.81540M -4.45608M -7.50115M
Issuance of capital stock 9.67M 9.32M 0.26M 19.10M -
Depreciation 0.18M 0.19M 0.18M 0.15M 0.04M
Other cashflows from investing activities - - - - -
Dividends paid - - - 0.03M -
Change to inventory - - - - -
Change to account receivables -0.37794M 0.27M -0.02869M -0.02869M -0.02869M
Sale purchase of stock 9.67M 9.32M 0.26M -1.21965M -1.21965M
Other cashflows from financing activities -0.18721M -0.16023M -0.12218M -0.09453M -0.09453M
Change to netincome 0.38M 0.68M -0.03137M -2.39202M 1.09M
Capital expenditures 0.06M 0.00583M 0.05M 0.02M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.37794M 0.27M -0.02869M 3.91M 4.49M
Stock based compensation 0.39M 0.59M -0.14080M -2.39088M -
Other non cash items -0.14860M 0.42M 1.43M 2.05M 8.53M
Free cash flow -11.37345M -10.11601M -8.86940M -4.47680M -0.01483M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OSL
Oncosil Medical Ltd		 -0.001 14.29% 0.006 - - 20.11 6.65 52.35 -0.6967
COH
Cochlear Ltd		 -3.32 1.13% 291.11 53.50 45.87 8.50 10.43 8.47 32.70
PNV
Polynovo Ltd		 -0.11 5.19% 2.01 206.00 138.89 13.79 20.21 13.83 352.63
AVH
Avita Therapeutics Inc		 -0.2 5.13% 3.70 - - 9.07 28.09 5.79 -10.0538
EBR
Ebr Systems Inc CDR		 0.12 14.53% 0.98 - - - 6.51 - -3.6785

Reports Covered

Stock Research & News

View All

Profile

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. Its lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

Oncosil Medical Ltd

7 Eden Park Drive, Macquarie Park, NSW, Australia, 2113

Key Executives

Name Title Year Born
Mr. Nigel Lange CEO, MD & Director NA
Mr. Karl David Pechmann CFO & Company Sec. NA
Mr. Michael Warrener Global Sales & Marketing Director NA
Dr. David Charles James Global Head of Manufacturing Operations NA
Dr. Ralph Peters Chief Medical Officer NA
Mr. David Turner Head of Medical Affairs NA
Mr. Christian Dal Cin CFO & Company Secretary NA
Mr. Christian Dal Cin CFO & Company Secretary NA
Mr. Christian Dal Cin CFO & Company Secretary NA
Mr. Christian Dal Cin CFO & Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.